Apellis' Lead Drug Tops Alexion's Blockbuster Soliris in a Pivotal Late-Stage Study

Apellis Pharmaceuticals (NASDAQ: APLS) announced results on Tuesday from its Pegasus late-stage clinical study evaluating experimental drug pegcetacoplan (APL-2) in treating adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder. The biotech company stated that pegcetacoplan achieved the primary efficacy endpoint of the study by producing greater improvement in patients' hemoglobin levels than Alexion Pharmaceuticals (NASDAQ: ALXN) Soliris.

This news caused Apellis stock to soar more than 20% Tuesday morning. Alexion's share price opened down more than 3% but later rebounded.

Image source: Getty Images.

Continue reading

Source Fool.com